Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06920758 · ClinicalTrials.gov registry record · NA
A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.
A NA study of Thinning Hair, sponsored by Ablon Skin Institute Research Center.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06920758: Active NA study of Thinning Hair, sponsored by Ablon Skin Institute Research Center.
NCT06920758 is a NA study of Thinning Hair that is active but no longer recruiting, run by Ablon Skin Institute Research Center. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06920758, a NA study of Thinning Hair, is active but no longer recruiting, sponsored by Ablon Skin Institute Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to substantiate the effectiveness and safety of USPlus® DERM for self-perceived thinning hair compared to placebo in healthy men and women ages 25-65 over the course of six months of continued use. Participants will be asked to have attend three office visits, one phone call, have photos taken of their hair and answer questionnaires related to their thinning hair.
Primary Outcome
Change in terminal hair counts from Baseline to Day 180 using the Canfield HairMetrix system. A statistically significant increase in count at Day 180 in comparison to Baseline for subjects who were assigned to the Active compared to subjects who were assigned to the placebo indicates an improvement for the indicated parameter.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT USPlus DERM Bioactive Fatty Acids 160 mg Softgels
- OTHER Placebo softgel
Study Locations (1)
California
- Ablon Skin Institute and Research Center - Manhattan Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2025-09 |
| Phase | NA |
What the registry record for NCT06920758 still lists
NCT06920758 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Thinning Hair appearing as the primary indexed condition, and to 2 interventions - of which USPlus DERM Bioactive Fatty Acids 160 mg Softgels is the first listed.
NCT06920758 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06920758 about?
NCT06920758 is a clinical study titled "A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.". The goal of this clinical trial is to substantiate the effectiveness and safety of USPlus® DERM for self-perceived thinning hair compared to placebo in healthy men and women ages 25-65 over the course of six months of continued use. Participants will be asked to have attend three office visits, one ...
What is the current status of trial NCT06920758?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2024-12-16. Estimated completion is 2025-09.
What conditions does trial NCT06920758 study?
This clinical trial studies the following conditions: Thinning Hair.
What interventions are being tested in trial NCT06920758?
The interventions under investigation include: USPlus DERM Bioactive Fatty Acids 160 mg Softgels (DIETARY_SUPPLEMENT), Placebo softgel (OTHER).
Who is sponsoring clinical trial NCT06920758?
This trial is sponsored by Ablon Skin Institute Research Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06920758 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thinning Hair
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06920758's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI